Proteolysis-targeting chimeric molecules (PROTACs) Market Size, Share, Growth Analysis, By Indication(Cancer, Autoimmune Diseases, and Neurodegenerative Disorders), By Technology(Bifunctional and Monovalent), By End-User(Pharmaceutical Companies, Academic and Research Institutions, and Contract Research Organizations (Cros)), By Region - Industry Forecast 2024-2031

Global Proteolysis-targeting chimeric molecules (PROTACs) market is characterized by several companies operating in the market, with different levels of market share and specialization. Competition of PROTACs is currently limited, with a few key players dominating the market. Arvinas, a biotech company, has emerged as a leader in the development of PROTACs, with several candidates in preclinical and clinical stages of development. Other companies, such as C4 Therapeutics and Kymera Therapeutics, have also entered the PROTACs space, with multiple candidates in various stages of development. Despite the limited competition, the potential for PROTACs to address previously undruggable targets has garnered significant attention from pharmaceutical companies, leading to numerous partnerships and collaborations in the field. Additionally, the development of PROTACs has spurred interest in related technologies, such as molecular glues and protein degraders, further expanding the competitive landscape of this emerging field.

Proteolysis-targeting Chimeric Molecules (PROTACs) Market Top Player’s Company Profiles

• AbbVie Inc.
• Arvinas, Inc.
• AstraZeneca plc
• Bayer AG
• Bristol Myers Squibb Company
• C4 Therapeutics, Inc.
• Cullgen Inc.
• Daiichi Sankyo Co., Ltd.
• GlaxoSmithKline plc
• Gilead Sciences, Inc.
• Kymera Therapeutics, Inc.
• Merck & Co., Inc.
• Nurix Therapeutics, Inc.
• Novartis AG
• Pfizer Inc.
• Proteolix, Inc.
• Progenra, Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Zenith Epigenetics Ltd.

Proteolysis-targeting Chimeric Molecules (PROTACs) Market Recent Developments

• In March 2023, Aileron Therapeutics announced the initiation of a Phase 1 clinical trial of its ALRN-6924 ProTac for the treatment of advanced solid tumors. The trial will evaluate the safety and efficacy of the drug in combination with chemotherapy.

• In February 2022, Zentalis Pharmaceuticals announced positive preliminary data from a Phase 1 clinical trial of its ZN-c3 ProTac for the treatment of solid tumors. The trial showed promising safety and efficacy data, with several patients experiencing partial responses.

• In January 2022, Vividion Therapeutics announced a $135 million series D financing round to advance its platform for developing small-molecule protein degraders, including ProTacs. The funds will be used to advance multiple drug candidates into the clinic.

• In December 2021, Kymera Therapeutics announced positive preclinical data for its lead ProTac candidate, KYM-001, for the treatment of solid tumors. The drug demonstrated significant tumor growth inhibition in multiple preclinical models.

• In November 2021, Nurix Therapeutics announced a collaboration with Gilead Sciences to develop novel ProTacs for the treatment of cancer and other diseases. The partnership will leverage Nurix's expertise in protein degradation and Gilead's experience in drug development.